Jarden weakness creates a buying opportuntiy, says Oppenheimer After Jarden reported higher than expected Q3 EPS but lower than expected organic sales, Oppenheimer expects the company's organic sales growth to reaccelerate in Q4 and 2013. The firm maintains an Outperform rating on the stock.
Jarden sees FY15 adj. EPS $2.75-$2.90, consensus $2.93 For 2015, the Company anticipates organic net sales growth to be within its long-term average target range of 3-5%. Including the negative impact of current foreign currency rates.